nodes	percent_of_prediction	percent_of_DWPC	metapath
Fondaparinux sodium—Wound secretion—Capecitabine—esophageal cancer	0.0327	0.0327	CcSEcCtD
Fondaparinux sodium—Cardiac tamponade—Methotrexate—esophageal cancer	0.0261	0.0261	CcSEcCtD
Fondaparinux sodium—Extravasation—Carboplatin—esophageal cancer	0.0251	0.0251	CcSEcCtD
Fondaparinux sodium—Prothrombin level decreased—Capecitabine—esophageal cancer	0.0247	0.0247	CcSEcCtD
Fondaparinux sodium—Bronchopneumonia—Capecitabine—esophageal cancer	0.0217	0.0217	CcSEcCtD
Fondaparinux sodium—Tetany—Cisplatin—esophageal cancer	0.0197	0.0197	CcSEcCtD
Fondaparinux sodium—Phlebitis—Carboplatin—esophageal cancer	0.0185	0.0185	CcSEcCtD
Fondaparinux sodium—Venous thrombosis—Cisplatin—esophageal cancer	0.0119	0.0119	CcSEcCtD
Fondaparinux sodium—Fluid overload—Cisplatin—esophageal cancer	0.0103	0.0103	CcSEcCtD
Fondaparinux sodium—Swelling face—Capecitabine—esophageal cancer	0.00995	0.00995	CcSEcCtD
Fondaparinux sodium—Intestinal perforation—Methotrexate—esophageal cancer	0.00892	0.00892	CcSEcCtD
Fondaparinux sodium—Venous thrombosis—Capecitabine—esophageal cancer	0.00878	0.00878	CcSEcCtD
Fondaparinux sodium—Necrosis—Cisplatin—esophageal cancer	0.00819	0.00819	CcSEcCtD
Fondaparinux sodium—Abscess—Cisplatin—esophageal cancer	0.00812	0.00812	CcSEcCtD
Fondaparinux sodium—Infection—Carboplatin—esophageal cancer	0.00777	0.00777	CcSEcCtD
Fondaparinux sodium—Haematoma—Capecitabine—esophageal cancer	0.00754	0.00754	CcSEcCtD
Fondaparinux sodium—Tenderness—Cisplatin—esophageal cancer	0.00737	0.00737	CcSEcCtD
Fondaparinux sodium—Extravasation—Cisplatin—esophageal cancer	0.00737	0.00737	CcSEcCtD
Fondaparinux sodium—Cellulitis—Cisplatin—esophageal cancer	0.00707	0.00707	CcSEcCtD
Fondaparinux sodium—Intestinal obstruction—Capecitabine—esophageal cancer	0.00695	0.00695	CcSEcCtD
Fondaparinux sodium—Haemoglobin decreased—Capecitabine—esophageal cancer	0.00689	0.00689	CcSEcCtD
Fondaparinux sodium—Ulcer—Cisplatin—esophageal cancer	0.0068	0.0068	CcSEcCtD
Fondaparinux sodium—Thrombosis—Capecitabine—esophageal cancer	0.00669	0.00669	CcSEcCtD
Fondaparinux sodium—Pain—Carboplatin—esophageal cancer	0.00669	0.00669	CcSEcCtD
Fondaparinux sodium—Blister—Capecitabine—esophageal cancer	0.00657	0.00657	CcSEcCtD
Fondaparinux sodium—Hepatocellular injury—Cisplatin—esophageal cancer	0.00643	0.00643	CcSEcCtD
Fondaparinux sodium—Haemoptysis—Capecitabine—esophageal cancer	0.0064	0.0064	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Carboplatin—esophageal cancer	0.00618	0.00618	CcSEcCtD
Fondaparinux sodium—Fluid retention—Cisplatin—esophageal cancer	0.0061	0.0061	CcSEcCtD
Fondaparinux sodium—Coagulopathy—Capecitabine—esophageal cancer	0.00609	0.00609	CcSEcCtD
Fondaparinux sodium—Tingling sensation—Capecitabine—esophageal cancer	0.00589	0.00589	CcSEcCtD
Fondaparinux sodium—Eruption—Methotrexate—esophageal cancer	0.00573	0.00573	CcSEcCtD
Fondaparinux sodium—Contusion—Capecitabine—esophageal cancer	0.00543	0.00543	CcSEcCtD
Fondaparinux sodium—Phlebitis—Cisplatin—esophageal cancer	0.00542	0.00542	CcSEcCtD
Fondaparinux sodium—Cellulitis—Capecitabine—esophageal cancer	0.00521	0.00521	CcSEcCtD
Fondaparinux sodium—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00521	0.00521	CcSEcCtD
Fondaparinux sodium—Hypocalcaemia—Capecitabine—esophageal cancer	0.00518	0.00518	CcSEcCtD
Fondaparinux sodium—Liver disorder—Methotrexate—esophageal cancer	0.00517	0.00517	CcSEcCtD
Fondaparinux sodium—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00515	0.00515	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Cisplatin—esophageal cancer	0.00505	0.00505	CcSEcCtD
Fondaparinux sodium—Ulcer—Capecitabine—esophageal cancer	0.00501	0.00501	CcSEcCtD
Fondaparinux sodium—Cyanosis—Methotrexate—esophageal cancer	0.00498	0.00498	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00476	0.00476	CcSEcCtD
Fondaparinux sodium—Fluid retention—Capecitabine—esophageal cancer	0.0045	0.0045	CcSEcCtD
Fondaparinux sodium—Necrosis—Methotrexate—esophageal cancer	0.00449	0.00449	CcSEcCtD
Fondaparinux sodium—Abscess—Methotrexate—esophageal cancer	0.00446	0.00446	CcSEcCtD
Fondaparinux sodium—Irritability—Cisplatin—esophageal cancer	0.00445	0.00445	CcSEcCtD
Fondaparinux sodium—Blood creatinine increased—Cisplatin—esophageal cancer	0.00437	0.00437	CcSEcCtD
Fondaparinux sodium—Dehydration—Cisplatin—esophageal cancer	0.00434	0.00434	CcSEcCtD
Fondaparinux sodium—Hypokalaemia—Cisplatin—esophageal cancer	0.00425	0.00425	CcSEcCtD
Fondaparinux sodium—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.0042	0.0042	CcSEcCtD
Fondaparinux sodium—Sepsis—Capecitabine—esophageal cancer	0.00411	0.00411	CcSEcCtD
Fondaparinux sodium—Extravasation—Methotrexate—esophageal cancer	0.00404	0.00404	CcSEcCtD
Fondaparinux sodium—Phlebitis—Capecitabine—esophageal cancer	0.00399	0.00399	CcSEcCtD
Fondaparinux sodium—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00394	0.00394	CcSEcCtD
Fondaparinux sodium—Sweating increased—Cisplatin—esophageal cancer	0.00393	0.00393	CcSEcCtD
Fondaparinux sodium—Swelling—Capecitabine—esophageal cancer	0.0039	0.0039	CcSEcCtD
Fondaparinux sodium—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00388	0.00388	CcSEcCtD
Fondaparinux sodium—Vascular purpura—Capecitabine—esophageal cancer	0.00384	0.00384	CcSEcCtD
Fondaparinux sodium—Oliguria—Methotrexate—esophageal cancer	0.00383	0.00383	CcSEcCtD
Fondaparinux sodium—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00373	0.00373	CcSEcCtD
Fondaparinux sodium—Ulcer—Methotrexate—esophageal cancer	0.00373	0.00373	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Capecitabine—esophageal cancer	0.00373	0.00373	CcSEcCtD
Fondaparinux sodium—Hot flush—Capecitabine—esophageal cancer	0.00368	0.00368	CcSEcCtD
Fondaparinux sodium—Menopausal symptoms—Capecitabine—esophageal cancer	0.00365	0.00365	CcSEcCtD
Fondaparinux sodium—Atrial fibrillation—Capecitabine—esophageal cancer	0.00363	0.00363	CcSEcCtD
Fondaparinux sodium—Renal impairment—Capecitabine—esophageal cancer	0.00361	0.00361	CcSEcCtD
Fondaparinux sodium—Dermatitis bullous—Capecitabine—esophageal cancer	0.0036	0.0036	CcSEcCtD
Fondaparinux sodium—Purpura—Capecitabine—esophageal cancer	0.00357	0.00357	CcSEcCtD
Fondaparinux sodium—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00354	0.00354	CcSEcCtD
Fondaparinux sodium—Renal failure—Cisplatin—esophageal cancer	0.00353	0.00353	CcSEcCtD
Fondaparinux sodium—Myocardial infarction—Cisplatin—esophageal cancer	0.00352	0.00352	CcSEcCtD
Fondaparinux sodium—Cardiac failure—Capecitabine—esophageal cancer	0.00352	0.00352	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00351	0.00351	CcSEcCtD
Fondaparinux sodium—Pain in extremity—Capecitabine—esophageal cancer	0.00344	0.00344	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0034	0.0034	CcSEcCtD
Fondaparinux sodium—Irritability—Capecitabine—esophageal cancer	0.00328	0.00328	CcSEcCtD
Fondaparinux sodium—Cardiac arrest—Capecitabine—esophageal cancer	0.00327	0.00327	CcSEcCtD
Fondaparinux sodium—Urinary retention—Capecitabine—esophageal cancer	0.00327	0.00327	CcSEcCtD
Fondaparinux sodium—Blood creatinine increased—Capecitabine—esophageal cancer	0.00322	0.00322	CcSEcCtD
Fondaparinux sodium—Dehydration—Capecitabine—esophageal cancer	0.0032	0.0032	CcSEcCtD
Fondaparinux sodium—Hypokalaemia—Capecitabine—esophageal cancer	0.00313	0.00313	CcSEcCtD
Fondaparinux sodium—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.0031	0.0031	CcSEcCtD
Fondaparinux sodium—Sepsis—Methotrexate—esophageal cancer	0.00306	0.00306	CcSEcCtD
Fondaparinux sodium—Gastritis—Capecitabine—esophageal cancer	0.00304	0.00304	CcSEcCtD
Fondaparinux sodium—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00303	0.00303	CcSEcCtD
Fondaparinux sodium—Flushing—Cisplatin—esophageal cancer	0.003	0.003	CcSEcCtD
Fondaparinux sodium—Abdominal distension—Capecitabine—esophageal cancer	0.00299	0.00299	CcSEcCtD
Fondaparinux sodium—Dysphagia—Capecitabine—esophageal cancer	0.00297	0.00297	CcSEcCtD
Fondaparinux sodium—Bronchospasm—Capecitabine—esophageal cancer	0.00292	0.00292	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Cisplatin—esophageal cancer	0.00292	0.00292	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Cisplatin—esophageal cancer	0.00291	0.00291	CcSEcCtD
Fondaparinux sodium—Sweating increased—Capecitabine—esophageal cancer	0.0029	0.0029	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Cisplatin—esophageal cancer	0.00288	0.00288	CcSEcCtD
Fondaparinux sodium—Bronchitis—Capecitabine—esophageal cancer	0.00286	0.00286	CcSEcCtD
Fondaparinux sodium—Malnutrition—Cisplatin—esophageal cancer	0.00281	0.00281	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Methotrexate—esophageal cancer	0.00277	0.00277	CcSEcCtD
Fondaparinux sodium—Flatulence—Cisplatin—esophageal cancer	0.00277	0.00277	CcSEcCtD
Fondaparinux sodium—Infestation NOS—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Fondaparinux sodium—Infestation—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Fondaparinux sodium—Vision blurred—Cisplatin—esophageal cancer	0.00265	0.00265	CcSEcCtD
Fondaparinux sodium—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00261	0.00261	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00261	0.00261	CcSEcCtD
Fondaparinux sodium—Renal failure—Capecitabine—esophageal cancer	0.00261	0.00261	CcSEcCtD
Fondaparinux sodium—Myocardial infarction—Capecitabine—esophageal cancer	0.0026	0.0026	CcSEcCtD
Fondaparinux sodium—Anaemia—Cisplatin—esophageal cancer	0.0026	0.0026	CcSEcCtD
Fondaparinux sodium—Urinary tract infection—Capecitabine—esophageal cancer	0.00258	0.00258	CcSEcCtD
Fondaparinux sodium—Haematuria—Capecitabine—esophageal cancer	0.00253	0.00253	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00251	0.00251	CcSEcCtD
Fondaparinux sodium—Epistaxis—Capecitabine—esophageal cancer	0.0025	0.0025	CcSEcCtD
Fondaparinux sodium—Irritability—Methotrexate—esophageal cancer	0.00244	0.00244	CcSEcCtD
Fondaparinux sodium—Convulsion—Cisplatin—esophageal cancer	0.00243	0.00243	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Capecitabine—esophageal cancer	0.00239	0.00239	CcSEcCtD
Fondaparinux sodium—Anxiety—Cisplatin—esophageal cancer	0.00238	0.00238	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Capecitabine—esophageal cancer	0.00238	0.00238	CcSEcCtD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00238	0.00238	CcSEcCtD
Fondaparinux sodium—Hypoaesthesia—Capecitabine—esophageal cancer	0.00237	0.00237	CcSEcCtD
Fondaparinux sodium—Oedema peripheral—Capecitabine—esophageal cancer	0.00234	0.00234	CcSEcCtD
Fondaparinux sodium—Oedema—Cisplatin—esophageal cancer	0.00229	0.00229	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Cisplatin—esophageal cancer	0.00229	0.00229	CcSEcCtD
Fondaparinux sodium—Infection—Cisplatin—esophageal cancer	0.00228	0.00228	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Cisplatin—esophageal cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Cisplatin—esophageal cancer	0.00225	0.00225	CcSEcCtD
Fondaparinux sodium—Tachycardia—Cisplatin—esophageal cancer	0.00224	0.00224	CcSEcCtD
Fondaparinux sodium—Skin disorder—Cisplatin—esophageal cancer	0.00223	0.00223	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Cisplatin—esophageal cancer	0.00222	0.00222	CcSEcCtD
Fondaparinux sodium—Flushing—Capecitabine—esophageal cancer	0.00221	0.00221	CcSEcCtD
Fondaparinux sodium—Anorexia—Cisplatin—esophageal cancer	0.00219	0.00219	CcSEcCtD
Fondaparinux sodium—Angiopathy—Capecitabine—esophageal cancer	0.00216	0.00216	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Capecitabine—esophageal cancer	0.00215	0.00215	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Capecitabine—esophageal cancer	0.00214	0.00214	CcSEcCtD
Fondaparinux sodium—Hypotension—Cisplatin—esophageal cancer	0.00214	0.00214	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Capecitabine—esophageal cancer	0.00213	0.00213	CcSEcCtD
Fondaparinux sodium—Malnutrition—Capecitabine—esophageal cancer	0.00207	0.00207	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Cisplatin—esophageal cancer	0.00206	0.00206	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Cisplatin—esophageal cancer	0.00204	0.00204	CcSEcCtD
Fondaparinux sodium—Flatulence—Capecitabine—esophageal cancer	0.00204	0.00204	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Capecitabine—esophageal cancer	0.00203	0.00203	CcSEcCtD
Fondaparinux sodium—Back pain—Capecitabine—esophageal cancer	0.002	0.002	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Cisplatin—esophageal cancer	0.00199	0.00199	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00198	0.00198	CcSEcCtD
Fondaparinux sodium—Infestation NOS—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Fondaparinux sodium—Infestation—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Fondaparinux sodium—Pain—Cisplatin—esophageal cancer	0.00196	0.00196	CcSEcCtD
Fondaparinux sodium—Vision blurred—Capecitabine—esophageal cancer	0.00195	0.00195	CcSEcCtD
Fondaparinux sodium—Renal failure—Methotrexate—esophageal cancer	0.00194	0.00194	CcSEcCtD
Fondaparinux sodium—Anaemia—Capecitabine—esophageal cancer	0.00191	0.00191	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Cisplatin—esophageal cancer	0.00189	0.00189	CcSEcCtD
Fondaparinux sodium—Haematuria—Methotrexate—esophageal cancer	0.00188	0.00188	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00187	0.00187	CcSEcCtD
Fondaparinux sodium—Epistaxis—Methotrexate—esophageal cancer	0.00186	0.00186	CcSEcCtD
Fondaparinux sodium—Vertigo—Capecitabine—esophageal cancer	0.00186	0.00186	CcSEcCtD
Fondaparinux sodium—Syncope—Capecitabine—esophageal cancer	0.00186	0.00186	CcSEcCtD
Fondaparinux sodium—Palpitations—Capecitabine—esophageal cancer	0.00183	0.00183	CcSEcCtD
Fondaparinux sodium—Loss of consciousness—Capecitabine—esophageal cancer	0.00182	0.00182	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Cisplatin—esophageal cancer	0.00181	0.00181	CcSEcCtD
Fondaparinux sodium—Cough—Capecitabine—esophageal cancer	0.00181	0.00181	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Methotrexate—esophageal cancer	0.00178	0.00178	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Methotrexate—esophageal cancer	0.00177	0.00177	CcSEcCtD
Fondaparinux sodium—Chest pain—Capecitabine—esophageal cancer	0.00176	0.00176	CcSEcCtD
Fondaparinux sodium—Anxiety—Capecitabine—esophageal cancer	0.00176	0.00176	CcSEcCtD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00175	0.00175	CcSEcCtD
Fondaparinux sodium—Confusional state—Capecitabine—esophageal cancer	0.0017	0.0017	CcSEcCtD
Fondaparinux sodium—Oedema—Capecitabine—esophageal cancer	0.00169	0.00169	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Cisplatin—esophageal cancer	0.00169	0.00169	CcSEcCtD
Fondaparinux sodium—Infection—Capecitabine—esophageal cancer	0.00168	0.00168	CcSEcCtD
Fondaparinux sodium—Shock—Capecitabine—esophageal cancer	0.00166	0.00166	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Capecitabine—esophageal cancer	0.00166	0.00166	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Capecitabine—esophageal cancer	0.00166	0.00166	CcSEcCtD
Fondaparinux sodium—Tachycardia—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Fondaparinux sodium—Asthenia—Cisplatin—esophageal cancer	0.00165	0.00165	CcSEcCtD
Fondaparinux sodium—Skin disorder—Capecitabine—esophageal cancer	0.00164	0.00164	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Capecitabine—esophageal cancer	0.00163	0.00163	CcSEcCtD
Fondaparinux sodium—Anorexia—Capecitabine—esophageal cancer	0.00161	0.00161	CcSEcCtD
Fondaparinux sodium—Angiopathy—Methotrexate—esophageal cancer	0.00161	0.00161	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Methotrexate—esophageal cancer	0.0016	0.0016	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Methotrexate—esophageal cancer	0.0016	0.0016	CcSEcCtD
Fondaparinux sodium—Hypotension—Capecitabine—esophageal cancer	0.00158	0.00158	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Cisplatin—esophageal cancer	0.00157	0.00157	CcSEcCtD
Fondaparinux sodium—Malnutrition—Methotrexate—esophageal cancer	0.00154	0.00154	CcSEcCtD
Fondaparinux sodium—Insomnia—Capecitabine—esophageal cancer	0.00153	0.00153	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Capecitabine—esophageal cancer	0.00152	0.00152	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Methotrexate—esophageal cancer	0.00151	0.00151	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Capecitabine—esophageal cancer	0.00151	0.00151	CcSEcCtD
Fondaparinux sodium—Back pain—Methotrexate—esophageal cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Capecitabine—esophageal cancer	0.00149	0.00149	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Capecitabine—esophageal cancer	0.00147	0.00147	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Vomiting—Cisplatin—esophageal cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Fatigue—Capecitabine—esophageal cancer	0.00146	0.00146	CcSEcCtD
Fondaparinux sodium—Vision blurred—Methotrexate—esophageal cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Rash—Cisplatin—esophageal cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Pain—Capecitabine—esophageal cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Constipation—Capecitabine—esophageal cancer	0.00145	0.00145	CcSEcCtD
Fondaparinux sodium—Dermatitis—Cisplatin—esophageal cancer	0.00144	0.00144	CcSEcCtD
Fondaparinux sodium—Anaemia—Methotrexate—esophageal cancer	0.00143	0.00143	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Capecitabine—esophageal cancer	0.00139	0.00139	CcSEcCtD
Fondaparinux sodium—Vertigo—Methotrexate—esophageal cancer	0.00139	0.00139	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00138	0.00138	CcSEcCtD
Fondaparinux sodium—Nausea—Cisplatin—esophageal cancer	0.00136	0.00136	CcSEcCtD
Fondaparinux sodium—Cough—Methotrexate—esophageal cancer	0.00135	0.00135	CcSEcCtD
Fondaparinux sodium—Urticaria—Capecitabine—esophageal cancer	0.00134	0.00134	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Capecitabine—esophageal cancer	0.00134	0.00134	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Capecitabine—esophageal cancer	0.00134	0.00134	CcSEcCtD
Fondaparinux sodium—Convulsion—Methotrexate—esophageal cancer	0.00134	0.00134	CcSEcCtD
Fondaparinux sodium—Chest pain—Methotrexate—esophageal cancer	0.00131	0.00131	CcSEcCtD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.0013	0.0013	CcSEcCtD
Fondaparinux sodium—Confusional state—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Methotrexate—esophageal cancer	0.00126	0.00126	CcSEcCtD
Fondaparinux sodium—Infection—Methotrexate—esophageal cancer	0.00125	0.00125	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Capecitabine—esophageal cancer	0.00125	0.00125	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Fondaparinux sodium—Skin disorder—Methotrexate—esophageal cancer	0.00122	0.00122	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Methotrexate—esophageal cancer	0.00122	0.00122	CcSEcCtD
Fondaparinux sodium—Asthenia—Capecitabine—esophageal cancer	0.00121	0.00121	CcSEcCtD
Fondaparinux sodium—Anorexia—Methotrexate—esophageal cancer	0.0012	0.0012	CcSEcCtD
Fondaparinux sodium—Pruritus—Capecitabine—esophageal cancer	0.0012	0.0012	CcSEcCtD
Fondaparinux sodium—Hypotension—Methotrexate—esophageal cancer	0.00118	0.00118	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Capecitabine—esophageal cancer	0.00116	0.00116	CcSEcCtD
Fondaparinux sodium—Insomnia—Methotrexate—esophageal cancer	0.00114	0.00114	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Methotrexate—esophageal cancer	0.00113	0.00113	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Methotrexate—esophageal cancer	0.00112	0.00112	CcSEcCtD
Fondaparinux sodium—Somnolence—Methotrexate—esophageal cancer	0.00112	0.00112	CcSEcCtD
Fondaparinux sodium—Dizziness—Capecitabine—esophageal cancer	0.00112	0.00112	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Methotrexate—esophageal cancer	0.00111	0.00111	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Methotrexate—esophageal cancer	0.00109	0.00109	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00109	0.00109	CcSEcCtD
Fondaparinux sodium—Fatigue—Methotrexate—esophageal cancer	0.00108	0.00108	CcSEcCtD
Fondaparinux sodium—Pain—Methotrexate—esophageal cancer	0.00108	0.00108	CcSEcCtD
Fondaparinux sodium—Vomiting—Capecitabine—esophageal cancer	0.00107	0.00107	CcSEcCtD
Fondaparinux sodium—Rash—Capecitabine—esophageal cancer	0.00107	0.00107	CcSEcCtD
Fondaparinux sodium—Dermatitis—Capecitabine—esophageal cancer	0.00106	0.00106	CcSEcCtD
Fondaparinux sodium—Headache—Capecitabine—esophageal cancer	0.00106	0.00106	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00103	0.00103	CcSEcCtD
Fondaparinux sodium—Nausea—Capecitabine—esophageal cancer	0.001	0.001	CcSEcCtD
Fondaparinux sodium—Urticaria—Methotrexate—esophageal cancer	0.001	0.001	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Methotrexate—esophageal cancer	0.000995	0.000995	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Methotrexate—esophageal cancer	0.000995	0.000995	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Methotrexate—esophageal cancer	0.000927	0.000927	CcSEcCtD
Fondaparinux sodium—Asthenia—Methotrexate—esophageal cancer	0.000903	0.000903	CcSEcCtD
Fondaparinux sodium—Pruritus—Methotrexate—esophageal cancer	0.00089	0.00089	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Methotrexate—esophageal cancer	0.000861	0.000861	CcSEcCtD
Fondaparinux sodium—Dizziness—Methotrexate—esophageal cancer	0.000832	0.000832	CcSEcCtD
Fondaparinux sodium—Vomiting—Methotrexate—esophageal cancer	0.0008	0.0008	CcSEcCtD
Fondaparinux sodium—Rash—Methotrexate—esophageal cancer	0.000793	0.000793	CcSEcCtD
Fondaparinux sodium—Dermatitis—Methotrexate—esophageal cancer	0.000793	0.000793	CcSEcCtD
Fondaparinux sodium—Headache—Methotrexate—esophageal cancer	0.000788	0.000788	CcSEcCtD
Fondaparinux sodium—Nausea—Methotrexate—esophageal cancer	0.000748	0.000748	CcSEcCtD
